当前位置：
X-MOL 学术
›
Adv. Healthcare Mater.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Bi2S3–Tween 20 Nanodots Loading PI3K Inhibitor, LY294002, for Mild Photothermal Therapy of LoVo Cells In Vitro and In Vivo
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2018-09-21 , DOI: 10.1002/adhm.201800830 Li Song 1, 2 , Xinghua Dong 1, 2 , Shuang Zhu 2 , Chunfang Zhang 1 , Wenyan Yin 2 , Xiao Zhang 2 , Xiangfeng Liu 1 , Zhanjun Gu 1, 2
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2018-09-21 , DOI: 10.1002/adhm.201800830 Li Song 1, 2 , Xinghua Dong 1, 2 , Shuang Zhu 2 , Chunfang Zhang 1 , Wenyan Yin 2 , Xiao Zhang 2 , Xiangfeng Liu 1 , Zhanjun Gu 1, 2
Affiliation
|
Although various types of photothermal agents are developed for photothermal cancer therapy, relatively few photothermal agents exhibit high tumor inhibition rate under relatively mild conditions. Herein, a multifunctional Bi2S3–Tween 20 nanoplatform loaded with PI3K inhibitor LY294002 is designed as a novel photothermal agent for inhibitor and photothermal synergistic therapy of tumors under mild photothermal therapy conditions. The LY294002 of PI3K inhibitor, after being loaded by Bi2S3–Tween 20 nanodots, exhibits greatly increased drug utilization and reduced side effects on normal tissues. In vivo, Bi2S3–Tween 20@LY294002 upon near‐infrared 808 nm laser irradiation shows potent antitumor activity under relatively mild conditions (power density: 0.6 W cm−2). Moreover, the mechanism studies also demonstrate that Bi2S3–Tween 20@LY294002 potently kills LoVo cancer cells under low‐power near‐infrared light irradiation, by downregulating the expression of heat shock protein 70 (HSP70) so as to increase the sensitivity of tumor cell hyperthermia and activating BAX/BAK‐regulated mitochondrial apoptosis pathway. The results demonstrate that the newly synthesized multifunctional nanoplatform paves a new avenue for accurate therapy of photothermal‐resistant cancer.
中文翻译：
Bi2S3–Tween 20纳米点加载PI3K抑制剂LY294002，用于体外和体内LoVo细胞的轻度光热疗法
尽管开发了多种类型的光热剂用于光热癌治疗，但是在相对温和的条件下，相对较少的光热剂表现出高的肿瘤抑制率。在本文中，负载PI3K抑制剂LY294002的多功能Bi 2 S 3 –Tween 20纳米平台被设计为在温和的光热治疗条件下用于肿瘤的抑制剂和光热协同治疗的新型光热剂。PI3K抑制剂的LY294002在被Bi 2 S 3 -Tween 20纳米点加载后，显示出极大的药物利用率，并减少了对正常组织的副作用。体内Bi 2 S 3–吐温20 @ LY294002在近红外808 nm激光辐照下显示出在相对温和的条件下（功率密度：0.6 W cm -2）有效的抗肿瘤活性。此外，机理研究还表明，Bi 2 S 3 –Tween 20 @ LY294002在低功率近红外光照射下可通过下调热休克蛋白70（HSP70）的表达来有效杀死LoVo癌细胞，从而提高敏感性。肿瘤细胞热疗和激活BAX / BAK调节的线粒体凋亡途径的作用。结果表明，新合成的多功能纳米平台为光热抗癌的精确治疗铺平了道路。
更新日期：2018-09-21
中文翻译：
Bi2S3–Tween 20纳米点加载PI3K抑制剂LY294002，用于体外和体内LoVo细胞的轻度光热疗法
尽管开发了多种类型的光热剂用于光热癌治疗，但是在相对温和的条件下，相对较少的光热剂表现出高的肿瘤抑制率。在本文中，负载PI3K抑制剂LY294002的多功能Bi 2 S 3 –Tween 20纳米平台被设计为在温和的光热治疗条件下用于肿瘤的抑制剂和光热协同治疗的新型光热剂。PI3K抑制剂的LY294002在被Bi 2 S 3 -Tween 20纳米点加载后，显示出极大的药物利用率，并减少了对正常组织的副作用。体内Bi 2 S 3–吐温20 @ LY294002在近红外808 nm激光辐照下显示出在相对温和的条件下（功率密度：0.6 W cm -2）有效的抗肿瘤活性。此外，机理研究还表明，Bi 2 S 3 –Tween 20 @ LY294002在低功率近红外光照射下可通过下调热休克蛋白70（HSP70）的表达来有效杀死LoVo癌细胞，从而提高敏感性。肿瘤细胞热疗和激活BAX / BAK调节的线粒体凋亡途径的作用。结果表明，新合成的多功能纳米平台为光热抗癌的精确治疗铺平了道路。
京公网安备 11010802027423号